疏血通注射液联合依达拉奉治疗急性脑梗死的临床观察
 |
| 第1页 |
参见附件(1977KB，2页)。
【摘要】 目的 观察疏血通注射液联合依达拉奉治疗急性脑梗死的疗效和安全性。方法 90例急性脑梗死患者随机分为治疗组(46例)与对照组(44例)，治疗组予疏血通注射液联合依达拉奉治疗，对照组予疏血通注射液治疗，观察两组患者治疗后美国国立卫生研究院卒中量表(NIHSS)评分的改善情况以及临床疗效。结果 治疗组在治疗后的NIHSS评分较对照组明显降低，差异有统计学意义(P<0.05)；治疗组的总有效率为87%，常规对照组为65.9%，差异有统计学意义(P<0.05)。结论 疏血通注射液联合依达拉奉能够促进急性脑梗死患者的神经功能康复、减少致残率、提高疗效，且无明显不良反应。
【关键词】 脑梗死；疏血通注射液；依达拉奉
Clinical observation on combining Shuxuetong injection with edaravone in treatment of patients with acute cerebral infarction
ZHEN Jun, LI Jing,YAO Xiao-li, et al. Department of Rehabilitation Medicine, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000,China
【Abstract】 Objective
To investigate the clinical effect and safetyof combining Shuxuetong injection with Edaravone in treatment of patients with acute cerebral infarction. Methods 90 patients with acute cerebral infarction were randomly divided into treatment group(46 cases)andcontrol group(44 cases),The treatment group received the treatment of combining Shuxuetong injection with Edaravone, while the control groupwas given Shuxuetong injection. The National Insitute of Health Stroke Scale(NIHSS)scores and the clinical effect were observed after treatment. Results After treatment the NIHSS scores in treatment group was significantly lower than that in control group, the differences was significant(P<0.05). Effective rate of treatment group was 87%,and the control group was 65.9%,the difference of the clinical effect between the two groups was significance(P<0.05).Conclusion Shuxuetong injectionwith Edaravone can promote recovery of nerve function, reduce disability rate, enhance the curative effect and there is no obvious adverse reaction.
【Key words】 Cerebral infarction; Shuxuetong injection; Edaravone
随着人口老龄化，我国脑卒中发病率呈逐年上升趋势,而目前针对性治疗脑卒中还没有取得突破性进展。现在临床上用于治疗脑梗死的药物很多，本研究应用疏血通注射液联合新型的脑神经保护剂依达拉奉治疗急性脑梗死46例，取得了较为满意的疗效，现将结果报告如下。
1 资料与方法
1.1 一般资料
选择2008年11月至2010年5月在本院住院的急性脑梗死患者90例，所有病例均符合1995年中华医学会第四届全国脑血管病学术会议修订的诊断标准[1]，并均经头颅CT或MRI证实。纳入标准：①首次发病，发病在72 h内。②发病年龄在25~80岁。③未进行过抗凝、溶栓、降纤治疗。④意识清楚、无痴呆与认知功能障碍。排除标准：①合并脑出血及其他系统出血倾向。②合并严重的心、肺、肝、肾功能不全。③药物过敏。采用随机数字表法将患者随机分为治疗组与对照组，其中治疗组46例，男26例，女20例，年龄45~78岁 ......
您现在查看是摘要介绍页，详见PDF附件(1977KB，2页)。